Literature DB >> 33644101

Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer.

Pasquale Pisapia1, Francesco Pepe1, Antonino Iaccarino1, Roberta Sgariglia1, Mariantonia Nacchio1, Floriana Conticelli1, Maria Salatiello1, Rossella Tufano2, Gianluca Russo1, Gianluca Gragnano1, Ilaria Girolami3, Albino Eccher4, Umberto Malapelle1, Giancarlo Troncone1.   

Abstract

Molecular cytopathology is a rapidly evolving field embracing both conventional microscopy and molecular pathology. Its growing popularity stems from the fact that in many types of advanced cancers, including non small cell lung cancer (NSCLC), cytological samples often constitute the only available specimens for morphomolecular analysis. Indeed, non formalin fixed and paraffin embedded (FFPE) cytological samples feature a higher quality of extracted nucleic acids than histological specimens. However, because of the growing complexity of molecular testing, several efforts should be made to validate the analytical performance of the wide array of currently available molecular technologies, including next generation sequencing (NGS). This technology has the terrific advantage of allowing simultaneous detection of scores of predictive biomarkers even in low-input DNA/RNA specimens. Here, we briefly review the role of the modern cytopathologist in the morphomolecular diagnosing of advanced stage NSCLC and the adoption of NGS in conventional cytopreparations (cell blocks, direct smears, and liquid-based cytology) and supernatants.
Copyright © 2021 Pisapia, Pepe, Iaccarino, Sgariglia, Nacchio, Conticelli, Salatiello, Tufano, Russo, Gragnano, Girolami, Eccher, Malapelle and Troncone.

Entities:  

Keywords:  NSCLC; cell block; cytopathology; fine needle aspiration; liquid based cytology; molecular cytopathology; smear

Year:  2021        PMID: 33644101      PMCID: PMC7904874          DOI: 10.3389/fmed.2021.633923

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  61 in total

1.  Performance comparison of benchtop high-throughput sequencing platforms.

Authors:  Nicholas J Loman; Raju V Misra; Timothy J Dallman; Chrystala Constantinidou; Saheer E Gharbia; John Wain; Mark J Pallen
Journal:  Nat Biotechnol       Date:  2012-05       Impact factor: 54.908

Review 2.  Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions.

Authors:  Douglas P Clark
Journal:  Cancer       Date:  2009-10-25       Impact factor: 6.860

Review 3.  Next-generation sequencing platforms.

Authors:  Elaine R Mardis
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2013       Impact factor: 10.745

Review 4.  To Obtain More With Less: Cytologic Samples With Ancillary Molecular Techniques-The Useful Role of Liquid-Based Cytology.

Authors:  Maurizio Martini; Sara Capodimonti; Tonia Cenci; Mirna Bilotta; Guido Fadda; Luigi Maria Larocca; Esther Diana Rossi
Journal:  Arch Pathol Lab Med       Date:  2018-03       Impact factor: 5.534

5.  Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology.

Authors:  Sinchita Roy-Chowdhuri; Sanja Dacic; Mohiedean Ghofrani; Peter B Illei; Lester J Layfield; Christopher Lee; Claire W Michael; Ross A Miller; Jason W Mitchell; Boris Nikolic; Jan A Nowak; Nicholas J Pastis; Carol Ann Rauch; Amita Sharma; Lesley Souter; Brooke L Billman; Nicole E Thomas; Paul A VanderLaan; Jesse S Voss; Momen M Wahidi; Lonny B Yarmus; Christopher R Gilbert
Journal:  Arch Pathol Lab Med       Date:  2020-05-13       Impact factor: 5.534

Review 6.  Molecular Diagnostics in Pathology: Time for a Next-Generation Pathologist?

Authors:  Matteo Fassan
Journal:  Arch Pathol Lab Med       Date:  2018-03       Impact factor: 5.534

7.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

8.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Authors:  David S Ettinger; Dara L Aisner; Douglas E Wood; Wallace Akerley; Jessica Bauman; Joe Y Chang; Lucian R Chirieac; Thomas A D'Amico; Thomas J Dilling; Michael Dobelbower; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Sandip P Patel; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-07       Impact factor: 11.908

9.  Assuring the quality of next-generation sequencing in clinical laboratory practice.

Authors:  Amy S Gargis; Lisa Kalman; Meredith W Berry; David P Bick; David P Dimmock; Tina Hambuch; Fei Lu; Elaine Lyon; Karl V Voelkerding; Barbara A Zehnbauer; Richa Agarwala; Sarah F Bennett; Bin Chen; Ephrem L H Chin; John G Compton; Soma Das; Daniel H Farkas; Matthew J Ferber; Birgit H Funke; Manohar R Furtado; Lilia M Ganova-Raeva; Ute Geigenmüller; Sandra J Gunselman; Madhuri R Hegde; Philip L F Johnson; Andrew Kasarskis; Shashikant Kulkarni; Thomas Lenk; C S Jonathan Liu; Megan Manion; Teri A Manolio; Elaine R Mardis; Jason D Merker; Mangalathu S Rajeevan; Martin G Reese; Heidi L Rehm; Birgitte B Simen; Joanne M Yeakley; Justin M Zook; Ira M Lubin
Journal:  Nat Biotechnol       Date:  2012-11       Impact factor: 54.908

10.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Authors:  Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton
Journal:  Genome Med       Date:  2017-04-19       Impact factor: 11.117

View more
  5 in total

1.  Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France).

Authors:  Marius Ilié; Véronique Hofman; Christophe Bontoux; Simon Heeke; Virginie Lespinet-Fabre; Olivier Bordone; Sandra Lassalle; Salomé Lalvée; Virginie Tanga; Maryline Allegra; Myriam Salah; Doriane Bohly; Jonathan Benzaquen; Charles-Hugo Marquette; Elodie Long-Mira; Paul Hofman
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

2.  Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma.

Authors:  Yue Zhao; Jun Shang; Jian Gao; Han Han; Zhendong Gao; Yueren Yan; Qiang Zheng; Ting Ye; Fangqiu Fu; Chaoqiang Deng; Zelin Ma; Yang Zhang; Difan Zheng; Shanbo Zheng; Yuan Li; Zhiwei Cao; Leming Shi; Haiquan Chen
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 3.  Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations.

Authors:  Antonio Marchetti; Fiamma Buttitta; Emanuela D'Angelo
Journal:  Oncotarget       Date:  2022-03-03

4.  The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling.

Authors:  Ling Qin; Ting Guo; Huaping Yang; Pengbo Deng; Qihua Gu; Chi Liu; Mengping Wu; Analyn Lizaso; Bing Li; Sa Zhang; Zhiqiu Chen; Chengping Hu
Journal:  Ann Transl Med       Date:  2022-04

5.  Targeted Sequencing of Ascites and Peritoneal Washing Fluid of Patients With Gastrointestinal Cancers and Their Clinical Applications and Limitations.

Authors:  Go Eun Bae; Seok-Hwan Kim; Min Kyung Choi; Jin-Man Kim; Min-Kyung Yeo
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.